NuVasive Management
Management criteria checks 3/4
NuVasive's CEO is Chris Barry, appointed in Nov 2018, has a tenure of 4.83 years. total yearly compensation is $8.08M, comprised of 11.1% salary and 88.9% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $2.90M. The average tenure of the management team and the board of directors is 3.7 years and 5.6 years respectively.
Key information
Chris Barry
Chief executive officer
US$8.1m
Total compensation
| CEO salary percentage | 11.1% |
| CEO tenure | 4.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.7yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Apr 18
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?
Jan 24NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price
Dec 31Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Dec 05These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well
Nov 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Sep 22Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Sep 01NuVasive Likely Undervalued, But It's Hard To Find Catalysts
Aug 17Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Aug 11NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M
Aug 03NuVasive: Industry Tailwinds More Than Fairly Priced
Jun 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jun 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
May 11NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Apr 20At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?
Mar 30NuVasive's Turnaround Story Needs A Boost From Better Results
Mar 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
Dec 28Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?
Dec 02NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Nov 11NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate
Oct 21Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital
Sep 29At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
Aug 18NuVasive Still Getting No Love With COVID-19 And Competitive Worries
Aug 12Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Jul 27Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?
Jun 17Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital
May 30Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All
May 12Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Mar 30Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?
Mar 09Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares
Feb 16
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jan 26NuVasive stock gains on study results of its X360 surgery approach
Jan 06What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Jan 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | US$28m |
| Mar 31 2023 | n/a | n/a | US$20m |
| Dec 31 2022 | US$8m | US$897k | US$40m |
| Sep 30 2022 | n/a | n/a | -US$20m |
| Jun 30 2022 | n/a | n/a | -US$40m |
| Mar 31 2022 | n/a | n/a | -US$37m |
| Dec 31 2021 | US$8m | US$875k | -US$64m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | US$2m |
| Mar 31 2021 | n/a | n/a | -US$50m |
| Dec 31 2020 | US$5m | US$735k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$9m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | US$61m |
| Dec 31 2019 | US$5m | US$800k | US$65m |
| Sep 30 2019 | n/a | n/a | US$48m |
| Jun 30 2019 | n/a | n/a | US$52m |
| Mar 31 2019 | n/a | n/a | US$49m |
| Dec 31 2018 | US$5m | US$92k | US$12m |
Compensation vs Market: Chris's total compensation ($USD8.08M) is above average for companies of similar size in the US market ($USD5.11M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Barry (50 yo)
4.8yrs
Tenure
US$8,077,095
Compensation
Mr. J. Christopher Barry, also known as Chris, serves as Chief Executive Officer and Director of NuVasive, Inc., since November 5, 2018. Mr. Barry served commercial and leadership roles at Covidien. He has...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$8.08m | 0.14% $ 2.9m | |
| Principal Accounting Officer | 3.7yrs | US$2.97m | 0.020% $ 418.2k | |
| Senior Vice President of Global Operations | 3.7yrs | US$1.48m | 0.017% $ 355.5k | |
| Senior VP | 5.3yrs | US$1.54m | 0.042% $ 869.2k | |
| Senior Vice President of People & Culture | less than a year | US$1.03m | 0.0059% $ 123.8k | |
| Senior VP & Chief Technology Officer | 2yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior Vice President of Strategy & Corporate Development | 3.8yrs | no data | no data | |
| Vice President & Head of Global Commercial Finance | 5.3yrs | no data | no data | |
| Senior Vice President of Information Technology | 1.7yrs | no data | no data | |
| Vice President | 5.3yrs | no data | no data |
3.7yrs
Average Tenure
48yo
Average Age
Experienced Management: NUVA's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.8yrs | US$8.08m | 0.14% $ 2.9m | |
| Independent Director | 5.6yrs | US$260.01k | 0% $ 0 | |
| Independent Director | 7.6yrs | US$260.01k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$280.01k | 0.0038% $ 79.4k | |
| Independent Director | 4.9yrs | US$260.01k | 0.0026% $ 54.0k | |
| Independent Chair | 8.2yrs | US$405.01k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$270.01k | 0.0059% $ 123.0k | |
| Independent Director | 2.6yrs | US$260.01k | 0.0071% $ 148.7k | |
| Independent Director | 2.1yrs | US$260.01k | 0% $ 0 |
5.6yrs
Average Tenure
59yo
Average Age
Experienced Board: NUVA's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/02 16:30 |
| End of Day Share Price | 2023/08/31 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NuVasive, Inc. is covered by 40 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Wittes | Aegis Capital Corporation |
| null null | Argus Research Company |
| Jeffrey Johnson | Baird |